In addition to age and extent of resection being prognostic, MGMT promoter methylation has been shown to associate with better response to treatment with alkylating agents like TMZ [6], although only a minority of GBM tumors have this molecular characteristic [7, 8]. This evidence concerns the gene MGMT and glioblastoma.